Update in the treatment of paediatric ulcerative colitis

Bibliography

• KUGATHASAN S, JUDD RH, HOFFMANN RG et al.: Wisconsin Pediatric Inflammatory Bowel Disease Alliance. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a state wide population-based study. J. Pediatr. (2003) 143:525-531.
   PubMed Web of Science ®Google Scholar
• HILDEBRAND H, FINKEL Y, GRAHNQUIST L, LINDHOM J, EKBOM A, ASKLING J: Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990 – 2001. Gut (2003) 52:1432-1434.
   PubMed Web of Science ®Google Scholar
• WEWER V, HESSELFELDT P, QVIST N, HUSBY S, PAERREGAARD A: J-Pouch ileoanal anastomosis in children and adolsescents with ulcerative colitis: functional outcome, satisfaction and impact on social life. J. Pediatr. Gastroenterol. Nutr. (2005) 40:189-193.
   PubMed Web of Science ®Google Scholar
• BREMNER AR, GRIFFITHS DM, BEATTIE RM: Current therapy of ulcerative colitis in children. Expert Opin. Pharmacother (2004) 5:37-53.
   PubMed Web of Science ®Google Scholar
• BOUMPAS DR, PALLOGIANNI F, ANASTASSIOU ED, BALOW JE: Glucocorticosteroid action on the immune system: molecular and cellular aspects. Clin. Exp. Rheumatol. (1991) 9:413-423.
   PubMed Web of Science ®Google Scholar
• BARNES PG, ADCOCK I: Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol. Sci. (2003) 14:436-441.
   Google Scholar
• BEATTIE RM, NICHOLLS SW, DOMIZIO P et al.: Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. (1996) 22:373-379
   PubMedGoogle Scholar
• HYAMS J, MARKOWITZ J, LERER T et al.: The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol. Hepatol. In Press.
   Google Scholar
• UCHIDA K, ARAKI T, TOIYAMA Y et al.: Preoperative steroid-related complications in Japanese pediatric patients with ulcerative colitis. Dis. Colon Rectum (2006) 49:74-79.
   PubMed Web of Science ®Google Scholar
• LEVINE A, WEIZMAN Z, BROIDE E et al.: A comparison of budesonide and prednisone for the treatment of active pediatric Crohn’s disease. J. Pediatr. Gastroenterol. Nutr. (2003) 36:248-252.
   PubMed Web of Science ®Google Scholar
• RIZZELLO F, GIONCHETTI P, D’ARIENZO A et al.: Oral beclometasone diproprionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment. Pharmacol. Ther. (2002) 16:1109-1116.
   PubMed Web of Science ®Google Scholar
• NIKOLAUS S, FOLSON U, SCHREIBER S: Immunopharmacology of 5-aminosalicylates and of glucocorticoids in the therapy of inflammatory bowel disease. Hepatogastroenterology (2000) 47:71-82.
   PubMed Web of Science ®Google Scholar
• MARAKHOUSKI Y, FIXA B, HOLOMAN J et al.: A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Aliment. Pharmacol. Ther. (2005) 21:133-140.
   PubMed Web of Science ®Google Scholar
• PRANTERA C, VISCIDO A, BIANCONE L, FRANCAVILLA A, GIGLIO L, CAMPIERI M: A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm. Bowel Dis. (2005) 11:421-427.
   PubMed Web of Science ®Google Scholar
• WIERSMA H, ESCHER JC, DILGER K et al.: Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease. Inflamm. Bowel Dis. (2004) 10:626-631.
   PubMed Web of Science ®Google Scholar
• SUTHERLAND L, ROTH D, BECK P, MAY G, MAKIYAMA K: Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis (Cochrane Review). In: The Cochrane Library, Issue 2. John Wiley, Chicester, UK (2004).
   Google Scholar
• SUTHERLAND L, MACDONALD JK: Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis (Cochrane Review). In: The Cochrane Library, Issue 2. John Wiley, Chicester, UK (2004).
   Google Scholar
• VAN STAATP, CARD T, LOGAN RF, LEUFKENS HG: 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut (2005) 54:1573-1578.
   PubMed Web of Science ®Google Scholar
• HANAUER SB, SANDBORN WJ, KORNBLUTH A et al.: Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am. J. Gastroenterol. (2005) 100:2478-2485.
   PubMed Web of Science ®Google Scholar
• MARTEAU P, PROBERT CS, LINDGREN S et al.: Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomized, double blind, placebo controlled study. Gut (2005) 54:960-965.
   PubMed Web of Science ®Google Scholar
• TIEDE I, FRITZ G, STRAND S et al.: CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. (2003) 111:1133-1145
   PubMed Web of Science ®Google Scholar
• MARKOWITZ J, GRANCHER K, KOHN N, DAUM F: Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990-2000. Am. J. Gastroenterol. (2002) 97:928-932.
   PubMed Web of Science ®Google Scholar
• DUBINSKY MC: Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastro Hepatol (2004) 2:731-743.
   PubMed Web of Science ®Google Scholar
• ARDIZZONE S, MACONI G, RUSSO A, IMBESI V, COLOMBO E, BIANCHI PORRO G: Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut (2006) 55:47-53.
   PubMed Web of Science ®Google Scholar
• KADER HA, MASCARENHAS MR, PICCOLI DA, STOUFFER NO, BALDASSANO RN: Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. (1999) 28:54-58.
   PubMed Web of Science ®Google Scholar
• KIRSCHNER BS: Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology (1998) 115:813-821.
   PubMed Web of Science ®Google Scholar
• SEIDMAN EG: Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in inflammatory bowel disease. Rev. Gastroenterol. Disord (2003) 3:S30-S38.
   PubMedGoogle Scholar
• KANDIEL A, FRASER AG, KORELITZ BI, BRENSINGER C, LEWIS JD: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut (2005) 54:1121-1125.
   PubMed Web of Science ®Google Scholar
• SHIBOLET O, REGUSHEVSKAYA E, BREZIS M, SOARES-WEISER K: Cyclosporin A for induction of remission in severe ulcerative colitis (Cochrane Review). In: The Cochrane Library, Issue 1. John Wiley, Chicester, UK (2005).
   Google Scholar
• PHAM CQ, EFROS CB, BERARDI RR: Cyclosporine for severe ulcerative colitis. Ann. Pharmacother. (2006) 40:96-101.
   PubMedGoogle Scholar
• TREEM WR, COHEN J, DAVIS PM, JUSTINICH CJ, HYAMS JS: Cyclosporin for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results and impact on surgery. Dis. Colon Rectum (1995) 38:474-479.
   PubMed Web of Science ®Google Scholar
• ROSENCRANTZ R, MOON A, RAYNES H, SPIVAK W: Cyclosporine-induced neurotoxicity during treatment of Crohn’s disease: lack of correlation with previously reported risk factors. Am. J. Gastroenterol. (2001) 96:2778-2782.
   PubMed Web of Science ®Google Scholar
• BAUMGART DC, WIEDENMANN B, DIGNASS AU: Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment. Pharmacol. Ther. (2003) 17:1273-1281.
   PubMed Web of Science ®Google Scholar
• BOUSVAROS A, KIRSCHNER BS, WERLIN SL et al.: Oral tacrolimus treatment of severe colitis in children. J. Pediatr. (2000) 137:794-799.
   PubMed Web of Science ®Google Scholar
• CUMMINGS JR, HERRLINGER KR, TRAVIS SP, GORARD DA, MCINTYRE AS, JEWELL DP: Oral methotrexate in ulcerative colitis. Aliment. Pharmacol. Ther. (2005) 21:385-389.
   PubMed Web of Science ®Google Scholar
• CAMPBELL MS, REDDY KR: Review article: the evolving role of liver biopsy. Aliment. Pharmacol. Ther. (2004) 20:249-259.
   PubMedGoogle Scholar
• SHEN C, MAERTEN P, GEBOES K, VAN ASSCHE G, RUTGEERTS P, CEUPPENS JL: Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. Clin. Immunol (2005) 115:250-259.
   PubMed Web of Science ®Google Scholar
• HANAUER SB, FEAGAN BG, LICHTENSTEIN GR et al.: Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet (2002) 59:1541-1549.
   Google Scholar
• RUTGEERTS P, SANDBORN WJ, FEAGAN BG et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. (2005) 353:2462-2476.
   PubMed Web of Science ®Google Scholar
• JARNEROT G, HERTERVIG E, FRIIS-LIVY I et al.: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology (2005) 128:1805-1811.
   PubMed Web of Science ®Google Scholar
• MAMULA P, MARKOWITZ JE, COHEN LJ, VON ALLMEN D, BALDASSANO RN: Infliximab in pediatric ulcerative colitis: two-year follow-up. J. Pediatr. Gastroenterol. Nutr. (2004) 38:298-301.
   PubMed Web of Science ®Google Scholar
• EIDELWEIN AP, CUFFARI C, ABADOM V, OLIVA-HEMKER M: Infliximab efficacy in pediatric ulcerative colitis. Inflamm. Bowel Dis. (2005) 11:213-218.
   PubMed Web of Science ®Google Scholar
• CHEIFETZ A, SMEDLEY M, MARTIN S et al.: The incidence and management of infusion reactions to infliximab: a large center experience. Am. J. Gastroenterol. (2003) 98:1315-1324.
   PubMed Web of Science ®Google Scholar
• JACOBSTEIN DA, MARKOWITZ JE, KIRSCHNER BS et al.: Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm. Bowel Dis. (2005) 11:442-446.
   PubMed Web of Science ®Google Scholar
• RIEGERT-JOHNSON DL, GODFREY JA, MYERS JL, HUBMAYR RD, SANDBORN WJ, LOFTUS EV Jr: Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis. (2002) 8:186-191.
   PubMed Web of Science ®Google Scholar
• VERMIERE S, NOMAN M, VAN ASSCHE G et al.: Automimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn’s disease: a prospective cohort study. Gastroenterology (2003) 125:32-39.
   Google Scholar
• BRATCHER JM, KORELITZ BI: Toxicity of infliximab in the course of treatment of Crohn’s disease. Expert Opin. Drug Saf. (2006) 5:9-16.
   PubMed Web of Science ®Google Scholar
• BOYER JF, JAMARD B, EL MAHOUS et al.: New onset acute heart failure and ventricular tachycardia after therapy with a tumor necrosis factor antagonist. Clin. Exp. Rheumatol. (2005) 23:274-275.
   PubMed Web of Science ®Google Scholar
• FRIESEN CA, CALABROC, CHRISTENSON K et al.: Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. (2004) 39:265-269.
   PubMed Web of Science ®Google Scholar
• DIMAAKOU K, PAPAIOANNIDES D, LATSI P, KATSIMBOULA S, KORANTZOPOULOS P, ORPAHNIDOU D: Disseminated tuberculosis complicating anti-TNF-alpha treatment. Int. J. Clin. Prac. (2004) 58:1052-1055.
   Google Scholar
• WOLFE F, MICHAUD K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. (2004) 50:1740-1751.
   PubMed Web of Science ®Google Scholar
• THAYU M, MARKOWITZ JE, MAMULA P, RUSSO PA, MUINOS WI, BALDASSANO RN: Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J. Pediatr. Gastroenterol. Nutr. (2005) 40:220-222.
   PubMed Web of Science ®Google Scholar
• FARRELL RG, ALSAHLI M, JEEN YT et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology (2003) 124:917-924.
   PubMed Web of Science ®Google Scholar
• BAERT F, NORMAN M, VERMEIRE S et al.: Influence of immunogenicity on the long term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med. (2003) 348:601-608.
   PubMed Web of Science ®Google Scholar
• RUTGEERTS P, FEAGAN BG, LICHTENSTEIN GR et al.: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology (2004) 126:402-413.
   PubMed Web of Science ®Google Scholar
• SANBORN WJ, YEDNOCK TA: Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am. J. Gastroenterol. (2003) 98:2372-2382.
   Google Scholar
• SANDBORN WJ, COLOMBEL JF, ENNS R et al.: Natalizumab induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med. (2005) 353:1912-1925.
   PubMed Web of Science ®Google Scholar
• HYAMS J, WILSON D, THOMAS A et al.: A Phase II, multicentre, open-label study of the safety, tolerability and effectiveness of natalizumab in adolescents with moderately to severely active Crohn’s disease. Presented at The 2nd World Congress of Pediatric Gastroenterology, Hepatology and Nutrition. Paris, France (3 – 7 July 2004).
   Google Scholar
• GORDON FH, HAMILTON MI, DONOGHUE S et al.: A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment. Pharmacol. Ther. (2002) 16:699-705.
   PubMed Web of Science ®Google Scholar
• KANDIEL A, FRASER AG, KORELITZ BI, BRENSINGER C, LEWIS JD: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut (2005) 54:1121-1125.
   PubMed Web of Science ®Google Scholar
• VAN ASSHCE G, VAN RANST M, SCIOT R et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med. (2005) 353:362-368.
   Google Scholar
• FEAGAN BG, GREENBERG GR, WILD G et al.: Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N. Engl. J. Med. (2005) 352:2499-2507.
   PubMed Web of Science ®Google Scholar
• BARISCH CF: Alicaforsen therapy in inflammatory bowel disease. Expert Opin. Biol. Ther. (2005) 5:387-391.
   Google Scholar
• VAN DEVENTER SJ, TAMI JA, WEDEL MK: A randomized, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut (2004) 53:1646-1651.
   PubMed Web of Science ®Google Scholar
• VAN ASSCHEG, RUTGEERTS P: Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am. J. Physiol. Gastrointest. Liver Physiol. (2005) 288:G169-G174.
   Web of Science ®Google Scholar
• CREED TJ, NORMAN MR, PROBERT CS et al.: Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colits. Aliment. Pharmacol. Ther. (2003) 18:65-67.
   PubMed Web of Science ®Google Scholar
• CREED T, PROBERT C, DAYAN C et al.: Basiliximab (anti-CD25) for the treatment of steroid resistant ulcerative colitis. Gastroenterology (2004) 126:A75.
   Google Scholar
• VAN ASSCHE G, DALLE I, NOMAN M et al.: A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am. J. Gastronterol. (2003) 98:369-376.
   PubMed Web of Science ®Google Scholar
• SCHWARZER A, RICCIARDELLI I, KIRKHAM S et al.: Management of fulminating ulcerative colitis in childhood with chimeric anti-CD25 antibody. J. Pediatr. Gastroenterol. Nutr. (2006) 42:245-248.
   Google Scholar
• PLEVY S, SALZBERG G, VAN ASSCHE et al.: A humanized anti-CD3 monoclonal antibody, visilizumab, for the treatment of severe steroid refractory ulcerative colitis: results of a Phase I study. Gastroenterology (2004) 126:A579.
   Google Scholar
• TARGAN S, SALZBERG B, MAYER L et al.: A Phase I-II: multi-dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients refractory to treatment with iv steroids (IVSR-UC). Gastroenterology (2005) 128:A493.
   Google Scholar
• CARPENTA PA, APPLEBAUM FR, COREY L et al.: A humanized non-FeR binding anti-CD3 antibody, visilizumab, for treatment of steroid refractory acute graft versus host disease. Blood (2002) 99:2712-2719.
   Google Scholar
• DOTON I, RACHMILEWITZ D: Probiotics in inflammatory bowel disease: possible mechanisms of action. Curr. Opin. Gastroenterol. (2005) 21:426-430.
   Google Scholar
• GUSLANDI M, GIOLLO P, TESTONI PA: A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur. J. Gastroenterol. Hepatol. (2003) 15:607-698.
   Google Scholar
• BIBLIONI R, FEDORAK RN, TANNOCK GW et al.: VSL3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am. J. Gastroenterol. (2005) 100:1539-1546.
   PubMedGoogle Scholar
• KATO K, MIZUNO S, UMESAKI Y et al.: Randomized placebo-controlled trial assessing the effect of bifidobacgteria-fermented milk on active ulcerative colitis. Aliment. Pharmacol. Ther. (2004) 20:1133-1141.
   PubMed Web of Science ®Google Scholar
• KRUIS W, FRIC P, POKROTNIEKS J et al.: Maintaining remission of ulcrative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut (2004) 53:1617-1623.
   PubMed Web of Science ®Google Scholar
• GIONCHETTI P, RIZZELLO F, HELWIG U et al.: Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology (2003) 124:1202-1209.
   PubMed Web of Science ®Google Scholar
• SUZUKI A, MITSUYAMA K, KOGA H et al.: Bifidogenic growth stimulator for the treatment of active ulcerative colitis: a pilot study. Nutrition (2006) 22:76-81.
   PubMed Web of Science ®Google Scholar
• FURRIE E, MACFARLANE S, KENNEDY A et al.: Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomized controlled pilot trial. Gut (2005) 54:242-249.
   PubMed Web of Science ®Google Scholar
• BOUSVAROS A, GUANDALINI S, BALDASSANO RN et al.: A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children. Inflamm. Bowel Dis. (2005) 11:833-839.
   PubMed Web of Science ®Google Scholar
• PLAYFORD RJ: Peptides and gastrointestinal mucosal integrity. Gut (1995) 37:595-597.
   PubMed Web of Science ®Google Scholar
• SINHA A, NIGHTINGALE J, WEST KP, BERLANG-ACOSTA J, PALYFORD RJ: Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N. Engl. J. Med (2003) 349:350-357.
   PubMed Web of Science ®Google Scholar
• MIYATA M, KASUGAI K, ISHIKAWA T, KAKUMU S, ONISHI M, MORI T: Rebamipide enemas-new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis. Dig. Dis. Sci. (2005) 50:S119-123.
   Web of Science ®Google Scholar
• MAKIYAMA K, TAKESHIMA F, HAMAMOTO T: Efficacy of rebamipide enemas in active distal ulcerative colitis and proctitis: a prospective study report. Dig. Dis. Sci (2005) 50:2323-2329.
   PubMed Web of Science ®Google Scholar
• LUGERING N, KUCHARZIK T, STOLL R et al.: Current concept of the role of monocytes/macrophages in inflammatory bowel disease- balance of proinflammatory and immunosuppressive mediators. Ital. J. Gastroenterol. Hepatol. (1998) 30:338-344.
   Google Scholar
• HANAI H, WATANABE F, YAMADA M et al.: Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion (2004) 70:36-44.
   PubMed Web of Science ®Google Scholar
• KRUIS W, DIGNASS A, STEINHAGEN-THIESSEN E et al.: Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J. Gastroenterol. (2005) 11:7001-7006.
   PubMed Web of Science ®Google Scholar
• SAWADA K, KUSUGAMI K, SUZUKI Y et al.: Leukocytaphereis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am. J. Gastroenterol. (2005) 100:1362-1369.
   PubMed Web of Science ®Google Scholar
• SAWADA K, EGASHIRA A, OHNISIHI K, FUKUNAGA K, KUSAKA T, SHIMOYAMA T: Leukocytaphereiss (LCAP) for management of fulminant ulcerative colitis with toxic megacolon. Dig. Dis. Sci. (2005) 50:767-773.
   PubMed Web of Science ®Google Scholar
• MORI Y, YOSHIHARA T, ANDO T et al.: Cytapheresis therapy for ulcerative colitis in three pediatric patients. J. Pediatr. Gastroenterol. Nutr. (2004) 39:485-486.
   Google Scholar
• TOMOMASA T, KOBAYASHI A, KANEKO H et al.: Granulocyte adsorptive apheresis for pediatric patients with ulcerative colitis. Dig. Dis. Sci. (2003) 48:750-754.
   PubMed Web of Science ®Google Scholar
• BOSCH T: Therapeutic apheresis – state of the art in the year 2005. Ther. Apher. Dial. (2005) 9:459-468.
   PubMedGoogle Scholar
• TRAVIS S, YAP L, HAWKEY CJ et al.: RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm. Bowel Dis. (2005) 11:713-719.
   PubMed Web of Science ®Google Scholar
• INGRAM JR, RHODES J, EVANS BK, THOMAS GA: Preliminary observations of oral nicotine therapy for inflammatory bowel disease: an open-label Phase I-II study of tolerance. Inflamm. Bowel Dis. (2005) 11:1092-1096.
   Google Scholar
• INGRAM JR, THOMAS GA, RHODES J et al.: A randomized trial of nicotine enemas for active ulcerative colitis. Clin. Gastroenterol. Hepatol. (2005) 3:1107-1114.
   PubMed Web of Science ®Google Scholar
• MCGRATH J, MCDONALD JW, MACDONALD JK: Transdermal nicotine for induction of remission in ulcerative colitis (Cochrane Review). In: The Cochrane Library, Issue 4. John Wiley, Chicester, UK (2004).
   Google Scholar
• SUMMERS RW, ELLIOTT DE, URBAN JF, THOMPSON RA, WEINSTOCK JV: Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology (2005) 128:825-832.
   PubMed Web of Science ®Google Scholar
• HYAMS JS, DAVIS P, GRANCHER K et al.: Clinical outcomes of ulcerative colitis in children. J. Pediatr. (1996) 129:81-88.
   PubMed Web of Science ®Google Scholar